Metraipolis › archive › dc_d5522bdaee31

Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial… — Europe PMC PMID:41001152

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41001152
DOI
10.3389/fnagi.2025.1619850
License (as archived)
solo-consultazione
Archived
2026-11-10T00:56:19.510Z
SHA-256 of the archived text
11c6501a4e3598bb26cce698c073f2f5d2413d79f66401a462501bdd99d27ac9
Stable URL of this page
https://metraipolis.com/documento/dc_d5522bdaee31

How to cite

Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial… — Europe PMC PMID:41001152 — Europe PMC (en), https://europepmc.org/article/MED/41001152 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d5522bdaee31 (Metraipolis archive dc_d5522bdaee31, sha256 11c6501a4e3598bb26cce698c073f2f5d2413d79f66401a462501bdd99d27ac9)
BibTeX
@misc{dcd5522bdaee31,
  title = {Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial… — Europe PMC PMID:41001152},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41001152},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d5522bdaee31; sha256 11c6501a4e3598bb26cce698c073f2f5d2413d79f66401a462501bdd99d27ac9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41001152. Agents can read the archived copy with the MCP tool read_document.